AccueilATBPF • OTCMKTS
add
Antibe Therapeutics
Dernière clôture
0,22 $
Plage sur l'année
0,11 $ - 0,89 $
Volume moyen
27,54 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (CAD) | déc. 2023info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 4,60 M | -1,42 % |
Résultat net | -4,21 M | 2,39 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | -0,08 | 0,50 % |
EBITDA | — | — |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (CAD) | déc. 2023info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 24,91 M | -41,20 % |
Total des actifs | 56,36 M | -23,56 % |
Total du passif | 30,42 M | -0,13 % |
Total des capitaux propres | 25,94 M | — |
Actions en circulation | 52,67 M | — |
Ratio cours/valeur comptable | 0,44 | — |
Rentabilité des actifs | -19,71 % | — |
Retour sur capitaux | -41,30 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (CAD) | déc. 2023info | Variation Y/Y |
|---|---|---|
Résultat net | -4,21 M | 2,39 % |
Trésorerie (opérations) | -3,84 M | -6,66 % |
Trésorerie (invest.) | 11,04 M | 1 975,38 % |
Trésorerie (financement) | — | — |
Variation nette en trésorerie | 7,20 M | 334,09 % |
Flux de trésorerie dispo. | -2,47 M | -2 419,13 % |
À propos
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Date de fondation
2009
Site Web
Employés
11
